OVID Stock Summary and Trading Ideas (Ovid Therapeutics | NASDAQ:OVID)

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.

As of March 9, 2026, OVID stock price climbed to $2.14 with 7,273,158 million shares trading.

OVID has a beta of 2.15, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.11 to the broad based SPY ETF.

OVID has a market cap of $152.39 million. This is considered a Micro Cap stock.

Last quarter Ovid Therapeutics reported $132,000 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-106,228 and missed earnings estimates by -$.02.

In the last 3 years, OVID traded as high as $4.14 and as low as $.24.

The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, VXF, BSVO, QQQS.

OVID has outperformed the market in the last year with a price return of +312.6% while the SPY ETF gained +19.7%. OVID has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.1% and +45.6%, respectively, while the SPY returned -0.8% and -1.6%, respectively.

OVID support price is $1.81 and resistance is $2.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.